調查批次:CHT2017-03 | 檢體寄出日期:2017-06-26 | 報告回收截止日期:2017-07-03 | 回收份數:22 |
T4 檢驗院際品管調查結果: | ||
2.歷次品管檢體 T4 檢驗值之實驗室間 CV 分佈圖 | ||
4.至本次各單位 z score 分佈圖 | 5.至本次各單位 D% 分佈圖 | 6.至本次各單位 SDI 分佈圖 |
檢驗單位 <代碼> |
確診醫院 <代碼> |
回報 天數 |
檢體 S1 |
檢體 S2 |
||||||||||||
( µg/dL ) |
D |
D% |
z |
SDI |
Da% |
( µg/dL ) |
D |
D% |
z |
SDI |
Da% |
|||||
RH01b | RH01 | 1 |
2 |
5 |
9.1 |
-1.3 |
-12.5 |
-1.6 |
0.0 |
-52 |
9.8 |
-1.2 |
-10.9 |
-1.4 |
0.0 |
-45 |
RH07b | RH07 | 4 |
2 |
3 |
9.1 |
-1.3 |
-12.5 |
-1.6 |
0.0 |
-52 |
10.2 |
-0.8 |
-7.3 |
-0.9 |
0.7 |
-30 |
RH15 | RH15 | 7 |
2 |
6 |
10.0 |
-0.4 |
-3.8 |
-0.5 |
1.5 |
-16 |
10.8 |
-0.2 |
-1.8 |
-0.2 |
1.8 |
-8 |
CL009 | CL009 | 4 |
2 |
5 |
8.5 |
-1.9 |
-18.3 |
-2.3 |
-1.0 |
-76 |
9.6 |
-1.4 |
-12.7 |
-1.6 |
-0.4 |
-53 |
CL010 | CL010 | 7 |
2 |
5 |
9.7 |
-0.7 |
-6.7 |
-0.8 |
1.0 |
-28 |
10.1 |
-0.9 |
-8.2 |
-1.0 |
0.5 |
-34 |
CL012 | CL012 | 8 |
2 |
3 |
9.1 |
-1.3 |
-12.5 |
-1.6 |
0.0 |
-52 |
9.4 |
-1.6 |
-14.5 |
-1.8 |
-0.7 |
-61 |
CL014a | CL014 | 4 |
2 |
5 |
8.6 |
-1.8 |
-17.3 |
-2.2 |
-0.8 |
-72 |
9.7 |
-1.3 |
-11.8 |
-1.5 |
-0.2 |
-49 |
CL015 | CL015 | 7 |
2 |
5 |
8.6 |
-1.8 |
-17.3 |
-2.2 |
-0.8 |
-72 |
9.1 |
-1.9 |
-17.3 |
-2.2 |
-1.3 |
-72 |
Median of RIA Group |
9.1 |
9.8 |
||||||||||||||
Range of RIA Group |
8.5 - 10.0 |
9.1 - 10.8 |
||||||||||||||
Robust mean of RIA Group |
9.1 ( n = 8 ) |
9.8 ( n = 8 ) |
||||||||||||||
Robust SD of RIA Group |
0.61 |
0.55 |
||||||||||||||
CV of RIA Group |
6.7% |
5.6% |
||||||||||||||
檢驗單位 <代碼> |
確診醫院 <代碼> |
回報 天數 |
檢體 S1 |
檢體 S2 |
||||||||||||
( µg/dL ) |
D |
D% |
z |
SDI |
Da% |
( µg/dL ) |
D |
D% |
z |
SDI |
Da% |
|||||
RH01a | RH01 | 3 |
4 |
9 |
10.1 |
-0.3 |
-2.9 |
-0.4 |
0.8 |
-12 |
11.7 |
0.7 |
6.4 |
0.8 |
1.1 |
27 |
RH02c | RH02 | 3 |
4 |
1 |
9.4 |
-1.0 |
-9.6 |
-1.2 |
-0.6 |
-40 |
10.4 |
-0.6 |
-5.5 |
-0.7 |
-0.3 |
-23 |
RH06 | RH06 | 7 |
4 |
9 |
10.1 |
-0.3 |
-2.9 |
-0.4 |
0.8 |
-12 |
12.1 |
1.1 |
10.0 |
1.3 |
1.6 |
42 |
RH07a | RH07 | 7 |
4 |
2 |
9.2 |
-1.2 |
-11.5 |
-1.4 |
-1.0 |
-48 |
9.7 |
-1.3 |
-11.8 |
-1.5 |
-1.1 |
-49 |
RH12 | RH12 | 4 |
4 |
2 |
9.5 |
-0.9 |
-8.7 |
-1.1 |
-0.4 |
-36 |
9.7 |
-1.3 |
-11.8 |
-1.5 |
-1.1 |
-49 |
RH14 | RH14 | 4 |
4 |
14 |
10.2 |
-0.2 |
-1.9 |
-0.2 |
1.0 |
-8 |
11.3 |
0.3 |
2.7 |
0.3 |
0.7 |
11 |
RH15b | RH15b | 4 |
4 |
13 |
10.0 |
-0.4 |
-3.8 |
-0.5 |
0.6 |
-16 |
10.7 |
-0.3 |
-2.7 |
-0.3 |
0.0 |
-11 |
RH19 | RH19 | 7 |
4 |
2 |
9.0 |
-1.4 |
-13.5 |
-1.7 |
-1.4 |
-56 |
9.7 |
-1.3 |
-11.8 |
-1.5 |
-1.1 |
-49 |
RH20 | RH20 | 7 |
4 |
7 |
10.2 |
-0.2 |
-1.9 |
-0.2 |
1.0 |
-8 |
11.9 |
0.9 |
8.2 |
1.0 |
1.4 |
34 |
CL005 | CL005 | 4 |
4 |
9 |
9.8 |
-0.6 |
-5.8 |
-0.7 |
0.2 |
-24 |
10.8 |
-0.2 |
-1.8 |
-0.2 |
0.1 |
-8 |
CL006a | CL006 | 7 |
4 |
7 |
9.5 |
-0.9 |
-8.7 |
-1.1 |
-0.4 |
-36 |
10.6 |
-0.4 |
-3.6 |
-0.5 |
-0.1 |
-15 |
CL008 | CL008 | 7 |
4 |
2 |
9.9 |
-0.5 |
-4.8 |
-0.6 |
0.4 |
-20 |
10.5 |
-0.5 |
-4.5 |
-0.6 |
-0.2 |
-19 |
CL011 | CL011 | 1 |
4 |
13 |
9.8 |
-0.6 |
-5.8 |
-0.7 |
0.2 |
-24 |
10.7 |
-0.3 |
-2.7 |
-0.3 |
0.0 |
-11 |
CL013b | CL013b | 4 |
4 |
1 |
8.9 |
-1.5 |
-14.4 |
-1.8 |
-1.6 |
-60 |
10.4 |
-0.6 |
-5.5 |
-0.7 |
-0.3 |
-23 |
Median of CLIA Group |
9.8 |
10.7 |
||||||||||||||
Range of CLIA Group |
8.9 - 10.2 |
9.7 - 12.1 |
||||||||||||||
Robust mean of CLIA Group |
9.7 ( n = 14 ) |
10.7 ( n = 14 ) |
||||||||||||||
Robust SD of CLIA Group |
0.49 |
0.88 |
||||||||||||||
CV of CLIA Group |
5.1% |
8.2% |
||||||||||||||
Median of All Labs |
9.5 |
10.4 |
||||||||||||||
Range of All Labs |
8.5 - 10.2 |
9.1 - 12.1 |
||||||||||||||
Robust mean of All Labs |
9.5 ( n = 22 ) |
10.4 ( n = 22 ) |
||||||||||||||
Robust SD of All Labs |
0.62 |
0.85 |
||||||||||||||
CV of All Labs |
6.5% |
8.2%
|
||||||||||||||
Certified assigned value ( Xa )( µg/dL ) |
10.4 |
11.0 |
||||||||||||||
Expanded uncertainty ( Ua ) |
0.100 |
0.109 |
||||||||||||||
Relative expanded uncertainty |
1.0% |
1.0% |
||||||||||||||
Coverage factor k |
2.6 |
2.5 |
||||||||||||||
Effective degrees of freedom veff |
5 |
6 |
||||||||||||||
SD for proficiency assessment ( σp ) |
0.832 |
0.880 |
||||||||||||||
Adjusted SD for proficiency assessment ( σp ' ) |
- |
- |
||||||||||||||
|
Method Code
|
Laboratory |
|
Radioimmunoassay ( Competitive-type ) |
2 |
RH01b, RH07b, RH15, CL009, CL010, CL012, CL014a, CL015, |
Chemiluminescent Immunoassay ( Competitive-type ) |
4 |
RH01a, RH02c, RH06, RH07a, RH12, RH14, RH15b, RH19, RH20, CL005, CL006a, CL008, CL011, CL013b, |
Reagent Code |
Laboratory |
|
Abbott Architect |
1 |
RH02c, CL013b, |
Beckman Coulter Access |
2 |
RH07a, RH12, RH19, CL008, |
Cisbio RIA-gnost |
3 |
RH07b, CL012, |
Immunotech |
5 |
RH01b, CL009, CL010, CL014a, CL015, |
MP |
6 |
RH15, |
Siemens ADVIA Centaur |
7 |
RH20, CL006a, |
Siemens Immulite 2000 |
9 |
RH01a, RH06, CL005, |
Roche |
13 |
RH15b, CL011, |
Johnson & Johnson ortho vitros |
14 |
RH14, |
若有任何疑問,歡迎來電(函)聯繫或指教
財團法人預防醫學基金會
地 址:10699 臺北信維郵局第 624 信箱 電 話:(02)
2703-6080
e-mail:
傳 真: (02)
2703-6070
updated
: 2017-07-05